Britannia Life Sciences Inc

As of June 30, 2026, BRITANNIA LIFE SCIENCES INC. has 164.59M shares outstanding.

As of June 30, 2026, BRITANNIA LIFE SCIENCES INC. maintains a current ratio of 5.69, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.96, indicating moderate leverage, while an interest coverage ratio of -65.15 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BRITANNIA LIFE SCIENCES INC. posted a return on equity (ROE) of 119.87, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -9.53, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 95.47, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 111.78, useful for judging operating efficiency across full business cycles.

Over the twelve months ended June 30, 2026, BRITANNIA LIFE SCIENCES INC. recorded 357,830.77 in income tax expense. That works out to an effective tax rate of 3.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.90M, leaving 11.65M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 21, 2026, BRITANNIA LIFE SCIENCES INC.'s stock has declined approximately 37.99% over the past 52 weeks.

Over the twelve months ended June 30, 2026, BRITANNIA LIFE SCIENCES INC. generated 286,381.86 in revenue and converted that into 11.65M in net income, yielding earnings per share of 0.06. EBITDA reached -994,456.07, while operating income came in at -997,612.76.

As of June 30, 2026, BRITANNIA LIFE SCIENCES INC. holds 8.75M in cash and equivalents against 149,038.55 in total debt, resulting in a net debt position of -8.26M. Total book value stands at 15.54M, with working capital of 8.41M providing operational flexibility.

BRITANNIA LIFE SCIENCES INC. produced -274,763.42 in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, BRITANNIA LIFE SCIENCES INC. posted a gross margin of 22.83, reflecting its pricing power and cost economics. The operating margin of -348.35 and net profit margin of 4,069.61 provide insight into operational efficiency.

BRITANNIA LIFE SCIENCES INC.'s most recent stock split took place on November 18, 2021 with a 10:1 split ratio.